How Biotech Short Sellers Think: The 7 Signals They Track

Most biotech investors spend 90% of their time building the bull case and 10% asking “what could go wrong.” Professional short sellers do the opposite. They start with “what kills this stock” and work backward.

Understanding how they think makes you a better long investor. The same red flags that attract short sellers are the ones that destroy your position without warning. Here are the seven signals they track, and how to check each one before you buy.

Signal 1: Trial Design Red Flags

Short sellers read ClinicalTrials.gov entries before they read press releases. They look for open-label single-arm studies where everyone knows what drug they’re getting. These trials produce stronger response rates than blinded randomized trials because there’s no placebo comparison and investigator bias creeps in.

They flag surrogate endpoints that haven’t been validated against survival. A drug that shrinks tumors but doesn’t extend life is a marketing story, not a validated medical advance. They also flag small sample sizes: a Phase 2 trial with 40 patients that shows a 60% response rate can drop to 25% in a properly powered Phase 3.

Real example: In August 2026, BioMarin discontinued BMN-401 after a $270 million write-off. Investors who only read the press releases missed the trial design warning signs that were visible on ClinicalTrials.gov months earlier.

Signal 2: Cash Runway Cliffs

A biotech with less than 12 months of cash is a forced seller. Short sellers divide cash and equivalents by the quarterly burn rate from the latest 10-Q. Under 12 months means dilution is coming: a secondary offering that typically drops the stock 20 to 30% on announcement. Under 6 months means the company is negotiating from weakness, and the terms will be brutal.

The pattern short sellers look for: companies that raise money after bad news, not before. A smart management team raises when the stock is strong and the data is clean. A desperate one raises after a trial miss, when every investor knows they have no negotiating position.

Signal 3: Insider Selling Patterns

Not all insider selling is a red flag. CEOs sell stock for tax reasons, estate planning, and pre-scheduled 10b5-1 trading plans. Short sellers look for the pattern that isn’t pre-scheduled: a CEO selling after positive Phase 2 data, a CFO leaving unexpectedly, multiple C-suite departures within six months.

The signal isn’t one trade. It’s the cluster. If the CEO, CFO, and CSO all sold stock in the same quarter, and none of it was scheduled, someone on the inside sees something the market doesn’t.

Signal 4: Endpoint Gaming

This is the most common way biotech companies spin failure as success. The trial’s primary endpoint was pre-specified on ClinicalTrials.gov before enrollment started. If the press release highlights a different endpoint, the trial failed on the one that mattered.

Short sellers check the “History of Changes” tab on every trial page. A primary endpoint that changed mid-trial is a flashing red light. So is a press release that leads with “key secondary endpoints” and buries the primary result on page three.

Real example: Biogen’s diranersen CELIA trial in Alzheimer’s missed its primary endpoint (dose response), but the press release led with “first study to show tau reduction and cognitive benefit.” An investor who read only the headline thought the trial succeeded. An investor who checked ClinicalTrials.gov saw the primary endpoint was dose response and that it missed. See the guide to reading clinical trial press releases for the full framework.

Signal 5: Competitive Shifts

Your drug works. Then a rival posts better Phase 2 data. Short sellers track the competitive dynamics obsessively because a better mousetrap kills your investment thesis regardless of your company’s execution.

The question they ask: if a competitor’s drug shows a 40% response rate and yours shows 25%, in the same indication, is your drug still approvable? The FDA doesn’t compare drugs head-to-head for approval. But doctors do. And payers do. A second-to-market drug with inferior data is a commercial failure waiting to happen.

Signal 6: FDA Division Headwinds

Not all FDA review divisions are equally strict. Some have higher CRL rates. Some are known for requesting additional data on specific endpoints. Short sellers track which division is reviewing which drug and what that division’s recent approval patterns look like.

The signal: if the reviewing division has rejected three of the last five drugs with similar trial designs, your stock’s PDUFA date is not a 63% probability of approval. It’s lower. The CRL base rate is 37% of all NDAs and BLAs between 2018 and 2022, but that number varies by division, drug class, and application type.

Signal 7: The Commercialization Gap

Approval is not the same as access. Short sellers look at pre-revenue biotechs and ask: who is going to sell this drug? If the company has no sales force, no manufacturing scale, no payer strategy, and no distribution agreement, the drug gets approved and still fails commercially.

A biotech that spent $500 million on R&D and zero on commercial infrastructure is a company that doesn’t know how to sell. Short sellers find these companies, short them before the approval, and cover after the disappointing launch numbers hit.

Real example: Bluebird bio (BLUE) had three approved gene therapies, including Zynteglo at $2.8 million per dose. But the company couldn’t secure reimbursement in Europe, wound down European operations, and by 2025 warned investors of insolvency risk. Great science, approved drugs, commercial failure. Short sellers saw the reimbursement gap years before the stock reflected it.

How to Use This as a Long Investor

Add a bear case checklist to every position. Before you buy, write three paragraphs explaining why someone would short this stock. If you can’t, you don’t understand the risk.

Then check each signal. Open-label trial? Smaller position. Less than 12 months of cash? Wait for the dilution. Endpoint change on ClinicalTrials.gov? Read the history before buying. Multiple insider sales in the same quarter? Find out if they were scheduled.

Short sellers aren’t your enemy. They’re the only people in the market asking the questions your bull case is avoiding. Learn from them.

For the broader framework on position sizing and risk management, see the guide to biotech investing fundamentals and the step-by-step FDA catalyst trading guide. For understanding the regulatory risk environment, the Complete Response Letter explainer covers what happens when the FDA says no.